前言结直肠癌(Colorectal Cancer, CRC)是最常见的

Introduction <br>Colorectal cancer (CRC) is the most common malignant tumor of the digestive tract, and its occurrence, development, diagnosis and treatment and prognosis are affected by many factors [1-2]. <br><br>In recent years, with the improvement of people's living standards and changes in eating habits, the incidence of colorectal cancer is on the rise. <br>The current common clinical treatment is radical tumor resection [3-5]. <br><br>However, according to the results of related reports, the 5-year survival rate of patients after radical resection of colorectal cancer is only about 50%-60%, and postoperative recurrence and metastasis are the main causes of death. <br><br><br>Circulating tumor cell (CTC) in the peripheral blood of tumor patients refers to cancer cells that break away from the tumor and enter the blood circulation. This remote metastasis is the main cause of death in tumor patients [6]. <br><br>Because it can be used to monitor tumor dynamics in real time, evaluate treatment effects, and achieve real-time individual treatment, it has become an important indicator of clinical liquid biopsy. <br><br>Timely and accurate detection of rare and very few CTCs is essential for the success of cancer treatment and improving the survival rate of patients. <br><br>In recent years, research on circulating tumor cells in colorectal cancer has gradually increased. Insua et al. realized the combined detection of CTC through a multi-gene expression platform to predict the prognosis and treatment effect of mCRC patients [7]. <br>Wu et al. used immunostaining-fluorescence in situ hybridization to detect the clinical significance of circulating tumor cells in colorectal cancer [8]. Garrigós et al. initially verified the study of circulating tumor cell analysis as an early marker of recurrence in patients with stage II and stage III colorectal cancer [9]. <br>Nevertheless, there are still a lot of gaps in the study of the mechanism of circulating tumor cells and gene levels in the peripheral blood of colorectal cancer.

Objective.<br>Colorectal Cancer (CRC) is the most common gastrointestinal malignancies, and its development, diagnosis and prognosis are influenced by a variety of factors.<br><br>In recent years, with the improvement of people's living standards and changes in eating habits, the incidence of colorectal cancer is on the rise.<br>At present, the treatment method commonly used in clinical practice is root-and-treat tumor excision.<br><br>However, according to the results of the relevant reports, after the treatment of colorectal cancer, the patient's five-year survival rate is only about 50%-60%, postoperative recurrence and metastasis is the leading cause of death.<br><br>Circulating tumor cells (circulating tumor cells) in the outer blood of tumor patients are cancer cells that break away from the tumor and enter the blood circulation, and this distant metastasis is the leading cause of death in tumor patients.<br><br>Because it can be used to monitor tumor dynamics in real time, evaluate the therapeutic effect, realize real-time individual treatment, become an important indicator of clinical liquid biopsy.<br><br>Timely and accurate detection of rare and rare CTCs is critical to the success of cancer treatment and to improving patient survival.<br><br>In recent years, the research on circulating tumor cells of colorectal cancer has gradually heated up. Insua and others achieved a joint detection of CTC through a multi-gene expression platform to predict the prognostic and therapeutic effects of mCRC patients.<br>Wu et al. used immuno-staining-fluorescence in-place hybridization to detect the clinical significance of circulating tumor cells in colorectal cancer. Garrigós et al. have initially validated studies on circulatory tumor cell analysis as an early marker of recurrence in patients with stage II and III colorectal cancer.<br>Nevertheless, there are still a lot of gaps in the study of the mechanism of circulating tumor cells and genes through the joint colorectal cancer.

preface<br>Colorectal cancer (CRC) is the most common malignant tumor of digestive tract. Its occurrence, development, diagnosis, treatment and prognosis are affected by many factors [1-2].<br>In recent years, with the improvement of people's living standard and the change of eating habits, the incidence rate of colorectal cancer is on the rise.<br>At present, the commonly used clinical treatment is radical tumor resection [3-5].<br>However, according to relevant reports, the 5-year survival rate of colorectal cancer patients after radical resection is only about 50% - 60%, and postoperative recurrence and metastasis are the main causes of death.<br>Circulating tumor cells (CTC) in the peripheral blood of tumor patients refer to cancer cells that break away from the tumor and enter the blood circulation. This remote metastasis is the main cause of death of tumor patients [6].<br>Because it can be used for real-time monitoring of tumor dynamics, evaluation of treatment effect and real-time individual treatment, it has become an important indicator of clinical fluid biopsy.<br>Timely and accurate detection of rare and rare CTC is crucial for the success of cancer treatment and the improvement of survival rate of patients.<br>In recent years, the research on circulating tumor cells of colorectal cancer is gradually warming up. Insua et al. Have realized the joint detection of CTC by multi gene expression platform to predict the prognosis and treatment effect of patients with MCRC [7].<br>Wu et al. Explored the clinical significance of circulating tumor cells in colorectal cancer by immunostaining fluorescence in situ hybridization [8]. Garrig ó s et al. Preliminarily verified the research on circulating tumor cell analysis as an early marker of recurrence in patients with stage II and III colorectal cancer [9].<br>However, there are still a lot of gaps in the study of tumor cell and gene mechanism of colorectal cancer combined with peripheral blood circulation.<br>